Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

IGFBP-1 Expression Promotes Tamoxifen Resistance in Breast Cancer Cells via Erk Pathway Activation

Frontiers in Endocrinology(2020)10.3389/fendo.2020.00233Source: DataRank Database

IGFBP-1 Expression Promotes Tamoxifen Resistance in Breast Cancer Cells via Erk Pathway Activation is a research paper published in Frontiers in Endocrinology (2020). On theSindex it has a DataRank of 0. It has been cited 31 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access31 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)Impact (FWCI 2.35)OA: goldTopics (65)IDs (PubMed, PMC, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (3)

Janel Y. Sowers,Kevin D. Houston ORCID,Zheng Yan ORCID

Live enrichment

PubMed:32435229 PMC:PMC7218143 OpenAlex:https://openalex.org/W3021216386

NIGMS NIH HHS

Grant: SC1 GM127175

NIGMS NIH HHS

Grant: T34 GM007667

National Institutes of Health

Grant: 1SC1GM127175-01A1

GPER1-dependent regulation of IGF-1R in tamoxifen treated breast cancer cells

National Institutes of Health

Grant: 3T34GM007667-19S1

BIOMEDICAL RESEARCH TRAINING FOR HONOR UNDERGRADUATES

National Institutes of Health

FWCI

2.35

Citation Percentile

0.9%

Citation Trend

2021

2022

2023

2024

2025

2026

goldLicense: cc-by

journalhttps://www.frontiersin.org/articles/10.3389/fendo.2020.00233/pdf

publisherhttps://www.frontiersin.org/articles/10.3389/fendo.2020.00233/pdf

publisherhttps://www.frontiersin.org/article/10.3389/fendo.2020.00233/full

journalhttps://doi.org/10.3389/fendo.2020.00233

repositoryhttps://pubmed.ncbi.nlm.nih.gov/32435229

Fields of Study

Growth Hormone and Insulin-like Growth FactorsCancer, Hypoxia, and MetabolismCancer-related Molecular Pathways0301 basic medicine03 medical and health sciences0303 health sciencesAntineoplastic Agents, HormonalApoptosisBiomarkers, TumorBreast NeoplasmsCell ProliferationDrug Resistance, NeoplasmFemaleGene Expression Regulation, NeoplasticHumansInsulin-Like Growth Factor Binding Protein 1Mitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3TamoxifenTumor Cells, Cultured

MeSH Terms

Breast NeoplasmsFemaleHumansTamoxifenTumor Cells, CulturedBiomarkers, TumorGene Expression Regulation, NeoplasticApoptosisAntineoplastic Agents, HormonalInsulin-Like Growth Factor Binding Protein 1Drug Resistance, NeoplasmMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3Cell Proliferation

Keywords

TamoxifenMAPK/ERK pathwayBreast cancerCancer researchMedicineInternal medicineSignal transductionBiologyCancerOncologyChemistryCell biologyDrug resistanceEGFRIGFBP-1Antineoplastic Agents, HormonalApoptosisBreast NeoplasmsDiseases of the endocrine glands. Clinical endocrinologyEndocrinologyBiomarkers, TumorTumor Cells, CulturedHumansCell ProliferationMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3RC648-665Gene Expression Regulation, NeoplasticInsulin-Like Growth Factor Binding Protein 1Drug Resistance, NeoplasmFemale

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being